Must resistance modify management of pneumonia and bacteraemia?;La résistance doit-elle modifier la prise en charge des pneumopathies et des bactériémies?

Medecine et Maladies Infectieuses

Volumn 32, Issue SUPPL. 1, 2002, Pages 61-70

  Bedos J P ^a   Moine, P ^b   Azoulay, E ^c  

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Beta lactams; Experimental infections; Pneumonia; Resistance; Streptococcus pneumoniae

Indexed keywords

AMINOPENICILLIN; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; GLYCOPEPTIDE; KETOLIDE; MACROLIDE; PRISTINAMYCIN; RIFAMPICIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CONCENTRATION RESPONSE; CONFERENCE PAPER; HUMAN; INFECTION RISK; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE; PNEUMONIA; STRAIN DIFFERENCE; STREPTOCOCCUS PNEUMONIAE;

EID: 18344395846     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-077X(02)80009-9     Document Type: Conference Paper

References (33)

1. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States
2. Épidémiologie des infections systémiques à Streptococcus pneumoniæ
3. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY antimicrobial surveillance program
4. Severe community acquired pneumonia: Epidemiology and prognosis factors
5. Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors
6. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit
7. A three-year study of severe community-acquired pneumonia with emphasis on outcome
8. Prognosis and outcome of patients with community-acquired pneumonia: A meta-analysis
9. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae
10. Enquête nationale sur les pneumonies communautaires à pneumocoque chez des malades adultes hospitalisés
11. Antimicrobial resistance of 1 113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1-year (1996-1997) multicenter surveillance study
12. Prevalence of gyrA, gyrB, parC and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season
13. Activities of a new fluoroketolide, HMR 3787 and its (des) fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clatithromycine and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes
14. Relation entre virulence et résistance aux antibiotiques des pneumocoques
15. Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae
16. Relationship between capsular type, penicillin susceptibility, and virulence of human Streptococcus pneumoniae isolates in mice
17. Complex relationship between acquisition of β-lactam resistance and loss of virulence in S. pneumoniae
18. Pneumonia cause by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: A case-control study
19. Severe community acquired pneumonia
20. Pneumonies à S. pneumoniæ de sensibilité diminuée à la pénicilline: Données épidémiologiques, facteurs de risque et impact thérapeutique
21. Amoxicillin remains effective against highly penicillin-resistant Streptococcus pneumoniae at dosing regimens simulating human pharmacokinetics in a mouse pneumonia model
22. Amoxicillin dose-effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains
23. Synergy between amoxicillin and gentamicin in combination against highly penicillin-resistant and -tolerant strain of Streptococcus pneumoniae in a mouse Pneumoniae model
24. Efficacy of cefotaxime in a murine model of penicillin-resistant pneumococcal pneumonia, with simulation of human pharmacokinetics
25. Efficacy of cefotaxime and ceftriazone in a mouse model of pneumonia induced by two penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae
26. In vivo activities of amoxicillin and amoxicillin-clavulanate againts Streptococcus pneumoniae: Application to breakpoint determinations
27. Pharmacodynamie in vitro de l'amoxicilline et bactericidie ex vivo après 1 g per os sur Streptococcus pneumoniæ résistant à la pénicilline
28. Streptococcus pneumoniae pneumonia in mice: Optimal amoxicillin dosing-predicted from a pharmacokinetic-pharmacodynamic model
29. Resistance to penicilline and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain
30. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence
31. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia
32. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
33. Association between Fc gamma R IIa-R131 allotype and bacteremic pneumococcal pneumonia